Hart C. Anthony, Shears Paul. Color Atlas of Medical Microbiology.pdf

Tuberculosis T 695

chronic 117

morphology 597

control 490 –491

graft-versus-host

murrelli 600

diagnosis 490, 625,

(GVH) reaction

nativa 600

646

115–116, 141

nelsoni 600

epidemiology 488

host-versus-graft

occurrence 597

gambiense 483,

(HVG) reactions 116,

prevention 601

485 –491, 646

141

pseudospiralis 600

life cycle 486 –487

hyperacute 116–117

pupuae 600

pathogenesis 489

measurement 117

spiralis 590 – 591,

rhodesiense 483,

syngeneic 116

597– 599, 600

485 –491, 646

xenogeneic 116

diagnosis 647, 654

see also Sleeping sick-

Transport of specimens

therapy 601

ness

bacteria 208

zimbabwensis 600

cruzi 483, 491–492

viruses 407, 409

Trichomonas vaginalis

clinical manifestations

Transposable elements

481– 482

492

(transposons) 173, 181

clinical manifestations

diagnosis 492, 625,

composite 173

482

647

conjugative 173, 177

diagnosis 482, 636

epidemiology

Tn3 173

epidemiology 481–482

491– 492

Transposase 181

life cycle 481

life cycle 491

Transposition 172, 181

occurrence 481

occurrence 491

Trematoda 545, 546

prevention 482

pathogenesis 492

diagnosis 640, 643

therapy 482

prevention 492

see also specific parasites

Trichomonosis see Tricho-

see also Chagas disease

Trench fever 334, 613

monas vaginalis

morphology 483–484

Treponema 320 – 324

Trichophyton spp. 355, 373

specimen handling 622,

carateum 320, 323 –324,

mentagrophytes 373, 374

623

651

rubrum 374

see also Trypanosomosis

pallidum 226, 322

tonsurans 374

Trypanosomatidae 483,

culture 320

see also Dermatophytes

484

diagnosis 321–322

Trichosporon

Trypanosomatidea 477

cutaneous infection

beigelii 355, 369, 374

Trypanosomosis

651

diagnosis 657

African 483, 485 –491

eye infections 655,

Trichuris trichiura (tri-

clinical manifestations

656, 657

churiosis) 544

488 –489

genital tract 637

clinical manifestations

diagnosis 490, 625

nervous system 645

580

distribution 485

endemicum 320, 323,

diagnosis 580, 640

epidemiology 488

651

life cycle 579 –580

prevention 490 –491

morphology 320

occurrence 579

therapy 490

pallidum 320–323

pathogenesis 580

American 483, 491– 492

pathogenesis

therapy 580

clinical manifestations

320 –321

Trimethoprim 190

492

pertenue 320, 323, 651

mechanisms of action

diagnosis 492, 625

see also Syphilis

198, 199

epidemiology

vincentii 631

Triplet code 181

491– 492

Trichinella (trichinellosis)

Tropheryma whipplei 261

occurrence 491

597– 601

diagnosis 639

prevention 492

britovi 600

Trophozoites 370

therapy 492

clinical manifestations

Tropical, pulmonary eosi-

see also Trypanosoma

599 –601

nophilia 590

Tsukamurella sp. 261

extraintestinal phase

Trypanosoma 483–492

Tsutsugamushi fever 330,

601

brucei 485

332

intestinal phase 601

antigenic variation

epidemiology 333

diagnosis 601, 626, 647

489

Tuberculin 264

muscle infection 654

brucei 484

reaction 99, 266

epidemiology 599

clinical manifestation

Tuberculosis

life cycle 597–599

488 –489

clinical picture 264–266

diagnosis 266–268

epidemiology 287

venereal diseases 637

rapid methods

therapy 285 –287

see also specific dis-

267–268

see also Salmonellae

eases

respiratory tract 632

Typhus 330, 332, 613

vulvovaginitis 364, 636

traditional method

epidemiology 331

see also specific infections

266–267

Tyroglyphus 612

urogenital tract 635

Tyrophagus 612

&V

epidemiology 268

immunity 99

&U

infection/immune re-

V factor 302

sponse relationship 104

Vaccination-associated

Mantoux test 99

Ulcers

paralytic poliomyelitis

mortality rates 268

acute necrotic ulcerous

(VAPP) 437

prevention 268

gingivostomatitis 631

Vaccines 32

disposition prophy-

duodenal 307, 638

BCG vaccine 268

laxis 268

gastric 307, 638

experimental 32

exposure prophylaxis

Ulcus molle 303

inactivated 32, 403

268

diagnosis 637

live attenuated 32, 403

primary 262, 264–265

Ureaplasma urealyticum

naked DNA vaccine 32,

pulmonary 265

228, 340, 341, 342

403

secondary 262,

diagnosis 635

poliomyelitis 437

265 –266

Urethral syndrome 635

purified microbial im-

source of infection 268

Urethritis 292, 338, 339,

munogens 32

therapy 267, 268

482

toxoids 32

transmission 268

diagnosis 635

with recombinant

Tuberculosis bacteria (TB)

non-gonococcal (NGU)

viruses 403

262, 263 –268

339

see also Immunization

cell wall 264

Urethrocystitis 292, 635

Vaccinia virus 426 –429

culture 264

Urinary tract infection see

Vaginitis (vaginosis) 252,

immunity 266

Urogenital infections

254, 482

morphology 263

Urine sampling 210, 623

diagnosis 636

pathogenesis 264–266

Urogenital infections 295

Vancomycin 191

see also Mycobacterium

cervicitis 636

mechanism of action

Tularemia 313, 316

chlamydiae 336, 339

198

diagnosis 648

diagnosis 210, 623,

Variant specific surface

Tumor immunity 107–108

635–637

antigens (VSSA) 486, 489

Tumor necrosis factor

E. coli 292 –293

Varicella-zoster virus

(TNF) 82

endometritis 636

(VZV) 418, 421–422

in malaria 528–529

listeriosis 636

clinical pictures 422

Tumor transformation

microsporidiosis 635

diagnosis 422

392, 394

mycoplasmas 341

cutaneous infection

carcinogenic retro-

nephropathica epidemi-

650

viruses 394– 396

ca 461, 635

eye infection 656

DNA tumor viruses 396

nosocomial infections

nervous system 645

Tunga penetrans (tungao-

344

epidemiology 422

sis) 618, 619–620

oophoritis 636

pathogenesis 421

biology 619

pelveoperitonitis 636

prevention 422

clinical manifestations

prostatitis 635

therapy 422

620

pyelonephritis 292, 635

Varicellovirus 382

diagnosis 620, 653

salpingitis 636

Variola virus 426–429

morphology 619

schistosomiasis 636

diagnosis 650

prevention 620

tuberculosis 635

Vectors 179, 181

therapy 620

urethritis 292, 339, 482,

bacteriophages 186

Turicella otitidis 261

635

viruses 390

Typhoid fever 280, 282,

urethrocystitis 292,

Venereal diseases 637

286

635

see also specific diseases

clinical picture 285

vaginitis (vaginosis) 252,

Verocytotoxins 288, 294

diagnosis 285, 639

254, 482, 636

Verruga peruana 649

Vibrio

classification 380 –381,

adsorption 384

cholerae 224, 296,

382 –383

DNA viruses 384–385,

297– 300

course of infection 398

387

antigens 297

culture see Viral culture

nucleic acid replica-

classification 297

defense mechanisms

tion 384–385

culture 297, 299

399 –402

penetration and un-

diagnosis 299, 639

nonspecific immune

coating 384

morphology 297

defenses 400–401

RNA viruses 385, 387

pathogenesis

specific immune de-

double-stranded

298–299

fenses 401–402

RNA 385, 387

source of infection

definition 376–377

single-stranded RNA

299

diagnosis see Laboratory

385, 387

toxin 16

diagnosis

size 377

transmission 299

dissemination in organ-

structural patterns

see also Cholera

ism 397– 398

379 –380

parahemolyticus 300

generalized infection

complex symmetry

diagnosis 638

396, 397–398

379

vulnificus 300

local infection 396,

cubic (rotational)

Viral capsid antigen (VCA)

397

symmetry 379

424

envelope 377, 378

helical symmetry 379,

Viral culture 406– 408

enzymes 379

380

amplification culture

excretion 399

transmission 397

408

genetics 389 –392

zoonoses 29

host system selection

genome 377–378, 380

see also specific viruses

408

segmented 388

Visceral larva migrans

identification 408

hemagglutinin 379

(VLM) 602 –605

information provided to

host-cell reactions

Angiostronglylus 604

laboratory 407

392 –394

Anisakis 604

laboratory processing of

cell destruction

Dirofilaria 605

material 407

392 –393

Toxocara 603 –604

sampling and transport

latent infection 394

Visceral leishmaniosis see

of specimens 407

tumor transformation

Leishmania (leishma-

significance of results

394

nioses)

408

virus replication

Vulvovaginitis 364

Viral proteins (VP) 388

without cell destruc-

diagnosis 636

Viremia, transitory 10

tion 393

Virion 377

host immunity evasion

&W

see also Viruses

102 –103

Viroids 472

identification 408

Virulence 8, 9, 11

maturation 388

Warts 413– 414

determinants of 7–11

morphology 377–380

diagnosis 650

regulation of 18–20

new viral species

molluscum contagiosum

Virulence genes 20 –21

391–392

428

Virulence plasmids 168,

nongenetic interactions

see also Papilloma-

177

391

viruses

Virulence protein secre-

pathogenesis 396 –399

Waterhouse-Friedrichsen

tion 17

antibody-dependent

syndrome 277

Virus infection factor (vif)

enhancement of in-

Wax D 264

449

fection 399

Weil disease see Leptospira

Viruses 4

portal of entry 397

interrogans (leptospirosis)

as vectors 390

prevention 402 –404

Weil-Felix agglutination

attenuated 390

protein synthesis

test 331

capsid 377, 378, 380

387–388

West Nile fever 443

characteristics 376

quasispecies 391

Western blotting 123, 125

chemotherapy 404–405

release from infected

Whipple’s disease 639

problems of 404–405

cells 388 –389

Whipworm 579 –580

resistance develop-

replication 381 –386,

Whooping cough (pertus-

ment 405

387

sis) 313, 315–316, 632